A single dose of respiratory syncytial virus (RSV) vaccine provides protection against RSV-associated hospitalization and critical illness in adults aged 60 years and older for two consecutive seasons, according to a new study from the IVY Network research group. The findings, published in JAMA , showed that the vaccination reduced the incidence of RSV-associated hospitalization by 58% combined over both seasons.

“These results clearly demonstrate that the RSV vaccines prevent hospitalizations and critical illness due to RSV infection among older Americans,” said Wesley Self, MD, principal investigator for the IVY Network and senior vice president for clinical research at Vanderbilt University Medical Center. “It is exciting to see the public health benefits of this new vaccination

See Full Page